LMU Klinikum der Universität München

München, Bavaria 81377

1 studies enrolling now · 5 studies all time

What they study most

BRAF or NRAS Mutant Metastatic Melanoma, Idiopathic Pulmonary Fibrosis, IgG4 Related Disease, Interstitial Lung Disease, Metastatic or Unresectable Cutaneous Melanoma, Non-small Cell Lung Cancer, Progressive Pulmonary Fibrosis

Studies at this site

• Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease — Enrolling by invitation
• A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease — Running, not enrolling
• A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma — Completed
• Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma — Completed
• TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy — Stopped early